Lung Cancer Trials Ask AI to find trials
RecruitingPhase 1 / Phase 2NCT07325136
Official study title

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

Study summary

The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedBMS-986525 and Pumitamig

The study team can explain what participation involves.

Who it may be forSmall cell lung cancer (SCLC) · Recurrent or relapsed · Resistant or refractory

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 14, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?13 U.S. locations

Locations may change over time.

Who runs it?Bristol-Myers Squibb

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1 / Phase 2
Sponsor
Bristol-Myers Squibb
Interventions being studied
Drug: BMS-986525; Drug: Pumitamig
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Small cell lung cancer (SCLC)→
Disease setting
Recurrent or relapsed→Resistant or refractory→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Participants must have histologically or cytologically documented relapsed/refractory small cell lung cancer (R/R-SCLC).
  • Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines.
  • In countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therapy, it is required that participants have progressed on, are ineligible for or not have access to an anti-PD- (L)1 therapy.
Reasons someone may not be able to joinExclusion criteria
  • Participants must not have any untreated CNS metastases.
  • Participants must not have an active, known or suspected autoimmune disease.
  • Participants must not have had a prior organ or tissue allograft.
  • Other protocol-defined Inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Karmanos Cancer InstituteDetroit, Michigan
  • Roswell Park Cancer InstituteBuffalo, New York
  • Duke Cancer InstituteDurham, North Carolina
  • University Hospitals Cleveland Medical CenterCleveland, Ohio
  • SCRI Oncology PartnersNashville, Tennessee
  • Local Institution - 0029Beijing, Beijing Municipality
  • Shanghai East HospitalShanghai, Shanghai Municipality
  • Istituto Clinico HumanitasRozzano, Milano
  • Local Institution - 0020Hirakata, Osaka
  • Local Institution - 0018Chuo-ku, Tokyo
  • Oncohelp Medical CenterTimișoara, Timiș County
  • Centrul de Oncologie Sf. Nectarie SRLCraiova

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 14, 2026. Always confirm current availability with the study team.

View original record ↗